GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » Net Cash per Share

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Net Cash per Share : $2.03 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Quoin Pharmaceuticals's Net Cash per Share for the quarter that ended in Mar. 2024 was $2.03.

The historical rank and industry rank for Quoin Pharmaceuticals's Net Cash per Share or its related term are showing as below:

QNRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.38   Med: 0.76   Max: 1.37
Current: 0.38

During the past 5 years, the highest Price-to-Net-Cash Ratio of Quoin Pharmaceuticals was 1.37. The lowest was 0.38. And the median was 0.76.

QNRX's Price-to-Net-Cash is ranked better than
98.27% of 866 companies
in the Biotechnology industry
Industry Median: 4.165 vs QNRX: 0.38

Quoin Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Quoin Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals Net Cash per Share Chart

Quoin Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
- -136.80 -21.77 14.37 4.24

Quoin Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.58 7.90 6.41 4.24 2.03

Competitive Comparison of Quoin Pharmaceuticals's Net Cash per Share

For the Biotechnology subindustry, Quoin Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quoin Pharmaceuticals's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's Price-to-Net-Cash falls into.



Quoin Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Quoin Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(10.695-6.505-0)/0.98722
=4.24

Quoin Pharmaceuticals's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(14.69-6.998-0)/3.79597
=2.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quoin Pharmaceuticals  (NAS:QNRX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Quoin Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Executives
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper director PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell director C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn officer: Chief Financial Officer AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter director, officer: Chief Operating Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers director, officer: Chief Executive Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Headlines